# Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome

> **NCT05702905** · PHASE4 · UNKNOWN · sponsor: **Peking University First Hospital** · enrollment: 75 (estimated)

## Conditions studied

- PCOS (Polycystic Ovary Syndrome)
- Semaglutide

## Interventions

- **DRUG:** Metformin Hydrochloride 500 MG
- **DRUG:** Semaglutide, 1.34 mg/mL
- **DRUG:** Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG
- **BEHAVIORAL:** calorie-restricted diet
- **BEHAVIORAL:** physical exercise

## Key facts

- **NCT ID:** NCT05702905
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-09
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05702905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05702905, "Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05702905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*